Sign In
29 Dec 2020 12:43
For immediate release | 29 December 2020 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Block Listing Six Monthly Return
Name of applicant: | ALLIANCE PHARMA PLC | |||
Names of schemes: | a) The Alliance Pharma plc Approved Share Option Plan 2005 b) The Alliance Pharma plc Share Option Plan 2006 c) The Alliance Pharma plc Company Share Option Plan 2015 | |||
Period of return: | From: | 28 June 2020 | To: | 28 December 2020 |
Number of securities originally admitted at date of admission: | 25,000,000 ordinary shares of 1p each 28 June 2017 | |||
Balance of unallotted securities under schemes from previous return: | a) 356,536 b) 5,362,778 c) 14,923,223 | |||
Plus: The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for): | a) Nil b) Nil c) Nil | |||
Less: Number of securities issued/allotted under schemes during period: | a) 63,164 b) 96,156 c) 1,701,727
| |||
Equals: Balance under schemes not yet issued/allotted at end of period: | a) 293,372 b) 5,266,622 c) 13,221,496 | |||
Name of contact: | Chris Chrysanthou, Company Secretary |
Telephone number of contact: | Tel. +44 (0)1249 705166 |
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black
Investec Bank plc +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar
About Alliance Pharma
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.
We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
Follow the stocks
